CDMO Almac is taking over some facilities abandoned by AstraZeneca in the U.K. some years back and will build them out to expand its own formulation and manufacturing operations.
Singapore has gathered pace as a place for companies in Asia to source services related to biologic clinical and manufacturing with recent additions in the city-state highlighting niches in a growing market.
Contract drug developer Almac has opened a new shop in Singapore, a facility that will serve as the company's Asian headquarters as it plots more investments in the region.
Multinational biologic trials in Asia are a "big driver" behind U.K.-based Almac Group's launch of a Singapore-based Asian headquarters, but business from emerging biotechs would be icing on the cake, company executives told FiercePharmaAsia in an interview.
Contract drug developer Almac has reached a milestone in its efforts to develop in-house therapeutics, taking its top prospect into Phase I trials.
Pharma outsourcer Almac has signed a deal that allows it to add emergency services to its clinical trial management platform, allowing sponsors to quickly handle unforeseen problems and minimize the need for unblinding data, the company said.
Contract developer Almac has earmarked £54 million ($90 million) to expand in its native Northern Ireland, planning to add 348 jobs over 5 years.
Almac Group saved some stellar news for the 2014 ASCO Annual Meeting in Chicago. The U.K. life sciences contract manufacturer said it validated a new diagnostic test that spots a subset of ovarian cancer patients with greater survival odds following standard chemotherapy who should avoid a specific Roche drug.
Contract developer Almac has signed a deal to license its technology to Genomic Health for breast cancer diagnostics, reaping $9 million with the chance for a bigger payday down the road.
Almac is expanding its contract manufacturing presence in Ireland, spending about $21.5 million to bolster a production facility and add 229 jobs.